FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates.
about
The role of FLT3 in haematopoietic malignanciesStructural and functional alterations of FLT3 in acute myeloid leukemiaThe CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cellsFiz1, a novel zinc finger protein interacting with the receptor tyrosine kinase Flt3Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AMLFunctional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.The Cytokine Flt3-Ligand in Normal and Malignant HematopoiesisTranscriptome dynamics during human erythroid differentiation and development.Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.The Biology and Targeting of FLT3 in Pediatric Leukemia.Beyond the RING: CBL proteins as multivalent adapters.Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational statusTreatment of FLT3-ITD acute myeloid leukemia.FLT3/ITD AML and the law of unintended consequences.FLT3: ITDoes matter in leukemia.Novel FLT3 tyrosine kinase inhibitors.Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling.Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.Bench to bedside targeting of FLT3 in acute leukemia.FLT3 inhibitors in acute myeloid leukemia.Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignanciesRNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable LiabilityFLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.FLT3/ITD mutation signaling includes suppression of SHP-1.Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment.Inhibition of USP10 induces degradation of oncogenic FLT3.CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin.A case of acute erythroleukemia with concurrence of BCR-ABL and FLT3-TKD (D835E) mutation.
P2860
Q24319174-5B5A0B5F-78EF-4899-8FCE-81C7A1AA70E5Q24338964-26403213-AA69-465D-B40B-D29D387B77B5Q28272735-182D65DA-957C-4D17-AD7C-EDA8D16B1644Q28505818-0BB1BEA8-6960-4132-AA71-CC31DAF6F834Q33647411-2FF4224E-6855-482D-BA71-8DA7C66FFB77Q33702150-24D22335-3765-46EF-9716-2172B31EA120Q33737486-A52CC576-91C4-4A31-BA3F-15C12AF1B7E3Q33767026-D9947BAB-0702-493C-861A-432908B66A71Q33838356-CA97B006-8EA2-434E-8473-6AF4FFED20D5Q34117785-A250D4C9-FAC2-402D-9510-BBC9FFB92448Q34133267-AAEA43D0-EAF5-4044-AB2E-CD062B2B1A7CQ34229555-0543D723-6B93-4132-9BCF-AED13628AF91Q34405560-602CC452-C924-4001-BA2A-9BDC127B133FQ34591403-4C45A924-C65B-4943-88A5-A5D0690E40CAQ34595162-2BB0E4E9-C978-43BB-A06D-0320BADF993CQ34636735-3FFDE2EA-7633-4372-B5ED-987157B9EF50Q35127958-9125DABE-745D-4D67-95C5-28AFA84C62DEQ35217399-D343AC1D-BE57-4964-8DAF-AE5B48D89B42Q35594041-FA93F0E5-4A3C-4530-B928-717F8B0A13A6Q35849949-4835B560-45E9-4FB2-8D40-F68E7B46CCE8Q36318153-66F20BFD-77CF-492E-A668-02CF11474900Q36368800-13548BC4-8FD0-4AEF-AB88-C2551AF27C7CQ37294768-D6907CED-600A-40EA-8BDA-C88667632684Q37724957-8628389F-C185-4F16-BF34-F5CA443A26ADQ37810061-66317B36-89B3-4E6F-9D1A-B1BFEF5BCD41Q38166527-D9FDBAB8-DDCC-4DC2-A76E-7468F80ACD54Q38720331-7B24CBC5-7CB6-43C7-80CA-15E504FDDD19Q38721796-796A8431-C235-4A5B-B615-8AFE46C8B237Q38943129-A8EF5278-F75B-4533-AEA0-7F7B32D0DA28Q39513601-40254E11-2616-4C36-9773-F7426B11E6BEQ40081796-B1E32DD2-0BA2-45AC-A720-B12C550A2ACEQ40218888-A9BAE519-EEBE-4CF0-B760-A99ED8382966Q40485872-FBBA6ABA-91E3-4F58-8F38-66AAFC23E487Q42229089-62D2A4AE-66D4-4A55-82A1-0502BE68B8DDQ47716589-3B8F818A-8D81-4409-80E9-ECB4E514FA80Q54329349-12EFC0BF-0063-474C-A203-0EC95BB1568FQ54546714-36E30B71-3094-4FFF-B281-089FC2A9A518Q55068988-6A657CE0-AFBF-489D-985E-E4461CC154CC
P2860
FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
FLT3 signaling in hematopoieti ...... ine-phosphorylated substrates.
@en
type
label
FLT3 signaling in hematopoieti ...... ine-phosphorylated substrates.
@en
prefLabel
FLT3 signaling in hematopoieti ...... ine-phosphorylated substrates.
@en
P2093
P356
P1433
P1476
FLT3 signaling in hematopoieti ...... ine-phosphorylated substrates.
@en
P2093
C Lavagna-Sévenier
D Birnbaum
S Marchetto
P2888
P304
P356
10.1038/SJ.LEU.2400921
P577
1998-03-01T00:00:00Z
P5875
P6179
1033772731